1. Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt
Gihan H. Elsisi, MSc, Zoltán Kaló, MSc, MD, PhD, Randa Eldessouki, MSc, MD, Mahmoud D. Elmahdawy, PharmD, Amr Saad, MSc, PhD, Samah Ragab, MPA, Amr M. Elshalakani, MD, MBA, Sherif Abaza, MBA 
Value in Health Regional Issues 
Volume 2, Issue 2, Pages (September 2013)
DOI: /j.vhri
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
Egypt in comparison with other middle-income countries in overall health care spending as percentage of gross domestic product. Data from USAID [1].
Value in Health Regional Issues 2013 2, DOI: ( /j.vhri )
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
The Egyptian pricing and reimbursement decision-making processes [26]. Bold boxes, decision-making bodies; boxes, decision influencer bodies; bold arrows, required step in the decision-making process; arrows, may or may not affect decision.
Value in Health Regional Issues 2013 2, DOI: ( /j.vhri )
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions